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The use of genetic data can be of great benefit in drug development.
When analysed with appropriate statistical methods, such resources
can be leveraged to identify potential drug targets and inform experi-
mental trials.1 It has been shown that drug development done with
the backing of genetic data is more likely to be successful.2 Increas-
ingly, pharmacological studies are able to harness the results of
genome-wide association studies (GWAS), which test for associations
between a phenotype and genetic variation across the entire genome.
Such studies are rapidly expanding in terms of both size of samples
and range of phenotypes.3 Although GWAS are able to identify many
genetic variants that are associated with a phenotypic trait of interest,
they are not able to provide, on their own, evidence as to which of
these associations are causal, or by which mechanisms these associa-
tions come about. New statistical methodology is being developed
which uses genetic data to help to answer these questions.
The study of Li et al.4 uses an integrative framework which com-
bines a number of analytical techniques with the aim of identifying
genes that may play a role in clozapine-related neutropenia. This is an
important problem because clozapine can be prescribed for
treatment-resistant schizophrenia but is underutilized due to potential
side effects such as neutropenia.4 Little is known about what makes a
patient susceptible to neutropenia while taking clozapine, and so by
identifying genes that may play a causal role in this process, insight
can be gained into the underlying biological mechanisms involved. Li
et al. use two sources of genetic data: GWAS summary statistics from
a study that measured neutrophil count in individuals during clozapine
treatment and summary statistics from a GWAS using expression
quantitative trait loci (eQTL) data, which identified associations
between genetic variants and gene expression levels. They apply
Mendelian randomization (MR) and colocalization analyses using
these datasets to identify relevant genes of interest and then
investigate these candidate genes further using gene set enrichment
analysis.
MR is a technique that uses genetic data to assess the effect of
an exposure on an outcome.5 A genetic variant that is associated with
the exposure of interest is used as a proxy, or instrument, for varying
that exposure. Because the genetic variants in an individual are
determined randomly at conception, they are typically independent of
environmental factors that can confound the exposure-outcome asso-
ciation. Thus, under certain assumptions, MR gives stronger evidence,
compared with typical observational studies, that detected associa-
tions represent causal effects.
In a pharmacological context, genetic variants that are associated
with the expression of a protein can be used as a proxy for perturbing
that protein, for example, via a drug. Methodological innovations
allow MR analyses to be performed by combining multiple genetic
variants associated with the same exposure and by using summary
level statistics from GWAS (that is, without requiring individual level
data).5 Although most polygenic MR methods require the genetic
instruments to be independent, applications in pharmacology typically
involve multiple genetic variants from the same gene region which will
be correlated (that is, in linkage disequilibrium). Recently, cis-MR tech-
niques have been developed to allow for such cases.6 The technique
applied by Li et al., probabilistic MR-Egger,7 was developed to perform
cis-MR in a transcriptome-wide framework, testing for the effect of
each gene region on the outcome.
Colocalization is a technique used to determine whether genetic
associations with two traits from separate studies are due to a shared
causal variant. The method of Giambartolomei et al.8 provides a test
of the colocalization hypothesis using GWAS summary statistics. Evi-
dence of a shared causal mechanism between a gene expression level
and a disease outcome identifies that gene as a potential target for
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pharmacological intervention. By applying this method using the gene
regions shown by MR to be potentially causal, Li et al. identified those
for which there is evidence of colocalization with neutrophil count
during clozapine treatment. Gene set enrichment analysis then
mapped these genes to biological pathways with which they are
associated. Their results give insight into the possible mechanisms
underlying clozapine-related neutropenia.
Although the approaches using genetic data discussed here can
be very powerful for providing pharmacological insights, a number of
considerations must be made. Each of the statistical methods make a
number of assumptions, and the strength of their conclusions hinge
on how well these can be justified. For example, the standard MR
framework requires the genetic instruments to have no horizontal
pleiotropy, that is, no association with the outcome other than via the
exposure. Recent developments in MR methodology allow for some
level of horizontal pleiotropy but only in return for making alternative
assumptions. For example, the probabilistic MR-Egger approach
allows for genetic variants to have horizontal pleiotropic effects on
the outcome, but only if these effects are independent of their effects
on the outcome via the exposure. This assumption will be violated, for
example, if any of the genetic variants associate with a confounder of
the exposure-outcome relationship. The validity of the colocalization
test employed by Li et al. relies on the assumption that there is at
most one association for each trait in the genetic region under consid-
eration. Not only are many of the assumptions required in these ana-
lyses quite strong, they are also often untestable. However,
consistent results from a range of approaches which make different
assumptions give weight of evidence to their conclusions.9
A further limitation to using genetic data to identify therapeutic
targets is the potential for index event bias, or collider bias. This can
occur when genetic associations with a trait are estimated in a sample
which has been selected based on a variable such as disease incidence.
If any genetic variants cause both the disease and the trait of interest,
then disease incidence is a potential collider, and conditioning the
sample on it may bias the genetic association estimates.10 As a result,
MR estimates may be biased. The outcome GWAS used by Li et al. was
performed in a sample of patients with drug-resistant schizophrenia. If
any genetic variants cause both schizophrenia and clozapine-related
neutropenia, then schizophrenia is a potential collider.
Another important consideration is the study population and the
ability to generalize findings. The study of Li et al. was done using
datasets taken from samples of individuals of African ancestry. On
one hand, this provides important information for this subpopulation,
particularly in light of the fact that the under-prescription of clozapine
may be particularly prevalent in this group.4 On the other hand, it may
limit the generalizability of the findings to the wider population. Ide-
ally, future studies would look to replicate the findings using samples
from broader population groups. However, this is not always easy,
particularly when using GWAS summary statistics, because the analy-
sis relies not only on a relevant GWAS existing, but also on the results
of the study being made publicly available. In the case of the study of
Li et al., while there are a number of GWAS that have been performed
looking at clozapine-related neutropenia, only one of them, which
studied individuals of African ancestry, has made summary statistics
available.4 This highlights the importance of GWAS consortia to
release summary statistics of their results.
Overall, the study of Li et al. demonstrates how the combination
of multiple cutting-edge statistical techniques applied to genetic data
can inform important questions in pharmacology, toward clinical
translation. It outlines a framework for an exploratory analysis to iden-
tify genes which are potentially causally related to a disease outcome
and possible mechanisms underlying these relationships. This in turn
provides a basis for future in-depth studies and experimental trials.
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